Farmakoterapia w Psychiatrii i Neurologii

Full text

1/2025 vol. 41
Case report

Psychosis in Huntington’s Disease: effectiveness of clozapine treatment – case report

Paweł Pruś 1
,
Jakub Daniluk 2
,
Justyna Chudy 2
,
Patryk Rodek 1
  1. Department and Clinic of Adult Psychiatry, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
  2. Student Scientific Organization of Department and Clinic of Adult Psychiatry, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
Farmakoterapia w Psychiatrii i Neurologii 2025, 41 (1), 43-47
DOI: https://doi.org/10.5114/fpn.2025.154612
Data publikacji online: 2025/10/30
Article file
4D0_IPiN_FARM_2025-1C.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS. Comorbidities of Obsessive and Compulsive Symptoms in Huntington’s Disease. Journal of Nervous & Mental Disease 2010; 198: 334–338.
  2. Bampton TJ, Hack D, Galletly CA. Clozapine treatment for Huntington’s disease psychosis. Aust N Z J Psychiatry 2022; 56: 200.
  3. Bonelli R, Wenning G. Pharmacological Management of Huntingtons Disease: An Evidence- Based Review. CPD 2006; 12: 2701–2720.
  4. Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, Squitieri F, Silani V. Aripiprazole in the treatment of Huntington’s disease: a case series. Neuropsychiatr Dis Treat 2009; 5: 1–4.
  5. De Berardis D, Rapini G, Olivieri L, Di Nicola D, Tomasetti C, Valchera A, Fornaro M, Di Fabio F, Perna G, Di Nicola M, Serafini G, Carano A, Pompili M, Vellante F, Orsolini L, Martinotti G, Di Giannantonio M. Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Ther Adv Drug Saf 2018; 9: 237–256.
  6. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, Eap CB. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117–125.
  7. Loi SM, Walterfang M, Velakoulis D, Looi JC. Huntington’s disease: Managing neuropsychiatric symptoms in Huntington’s disease. Australas Psychiatry 2018; 26: 376–380.
  8. Lowe EJ, Ackman ML. Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment. Ann Pharmacother 2010; 44: 727–732.
  9. Majothi N, Lee HY, Nagarajan P, Vutla R. Treatment of psychosis in Huntington’s disease with clozapine. Prog Neurol Psychiatry 2020; 24: 14–16.
  10. Malinowska-Kubiak M, Permoda-Osip A. Use of three antipsychotics in long-acting injections in a patient with psychotic symptoms, in the course of Huntington’s disease – case report. Pharmacotherapy in Psychiatry and Neurology 2017; 33 (1): 67–75.
  11. Meltzer HY, 2012. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6: 134–144.
  12. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123: 411–422.
  13. Roos RA. Huntington’s disease: a clinical review. Orphanet J Rare Dis 2010; 5: 40.
  14. Rosenblatt A, Leroi I. Neuropsychiatry of Huntington’s Disease and Other Basal Ganglia Disorders. Psychosomatics 2000; 41: 24–30.
  15. Rossi M, Farcy N, Starkstein SE, Merello M. Nosology and Phenomenology of Psychosis in Movement Disorders. Mov Disord Clin Pract 2020; 7: 140–153.
  16. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16: 23–45.
  17. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 2014a; 4: e004216.
  18. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open 2014b; 4: e004216.
  19. Van Duijn E, Kingma EM, Van Der Mast RC. Psychopathology in Verified Huntington’s Disease Gene Carriers. JNP 2007; 19: 441–448. https://doi.org/10.1176/jnp.2007.19.4.441
  20. Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, Marcinkowski JT, Landwehrmeyer GB. The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington’s disease. Parkinsonism & Related Disorders 2018; 49: 42–47.
SUBMIT YOUR PAPER
Share
without publication fees
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications